Amplimune, mycobacterium cell wall fraction (MCWF) immunostimulant, is approved by the USDA for the treatment of bovine infectious
disease. Amplimune is recommended as a one time immunotherapeutic treatment for the reduction of clinical signs and mortality
associated with enterotoxigenic Escherichia coli (ETEC) K99 diarrhea in neonatal calves. Colibacillosis caused by ETEC K99 is one
of the principal causes of neonatal calf diarrhea. ETEC infection occurs most frequently in the first week of life, before the calf
can become resistant to the disease. Early treatment of colibacillosis must be directed toward the control of the bacteria in the
intestinal tract. Studies indicate that the optimum times at which to administer Amplimune are: Early in the disease process, and
on farms with persistent E. coli scours, treating all calves immediately, 1 day after birth. OMRI Listed, USDA Licensed.
disease. Amplimune is recommended as a one time immunotherapeutic treatment for the reduction of clinical signs and mortality
associated with enterotoxigenic Escherichia coli (ETEC) K99 diarrhea in neonatal calves. Colibacillosis caused by ETEC K99 is one
of the principal causes of neonatal calf diarrhea. ETEC infection occurs most frequently in the first week of life, before the calf
can become resistant to the disease. Early treatment of colibacillosis must be directed toward the control of the bacteria in the
intestinal tract. Studies indicate that the optimum times at which to administer Amplimune are: Early in the disease process, and
on farms with persistent E. coli scours, treating all calves immediately, 1 day after birth. OMRI Listed, USDA Licensed.